Pfizer, Medivation Alzheimer Drug Fails in Phase III

Dimebon, an investigational drug co-developed by Pfizer and Medivation, failed its Phase III trial in Alzheimer’s disease. The compound failed to meet its co-primary and secondary efficacy endpoints — cognition and global function — compared to placebo in the CONNECTION trial. Dimebon was well-tolerated in its separate Phase III safety and tolerability study, when dosed alone or in combination with approved Alzheimer’s medicines.

“We are evaluating the CONNECTION data with Medivation. After that review, Pfizer will be in a position to determine appropriate next steps regarding the dimebon program,” said Dr. Briggs W. Morrison, senior vice president, clinical development, Primary Care Business Unit at Pfizer. “We recognize the significant medical need, and we are committed to advancing treatment options for Alzheimer’s disease.”